Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:0 ...

Addex receives CHF5M and 20% share of Neurosterix  Perceptive Advisors leads $63M investment into Neurosterix  Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, and funds affiliated ...

Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event. In his presentation, Mr Dyer will provide a corporate update and discuss recent developments at Addex. ...

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex's CNS pipeline. Presentation Details:Date: T ...

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex’s CNS pipeline. Presentation Detail ...

CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024. In his presentation, scheduled for Monday January 8, 2024 at 4:30 PM PT (01:30 AM CET), Mr Dyer wi ...

CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024. In his presentation, scheduled for Monday January 8, 2024 at 4:30 PM PT (01:30 AM CET), M ...

Innovative Treatments for Central Nervous System Disorders November 2023 Allosteric modulators for human health Disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decisio ...

Addex Therapeutics Ltd. (NASDAQ:ADXN) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speake ...

Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and nine-month periods ended September 30, 2023 and 20223 Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the nine- ...